DEVELOPMENT OF AN ALTERNATIVE METHOD TO DETERMINE THE PRESENCE OF ANTIBODIES AGAINST SARS-COV-2 ANTIGENS IN PATIENT SERA AND TO ANALYZE THE CHARACTERISTICS OF THE HUMORAL IMMUNE RESPONSE

NOLI TRUANT, SOFIA; REDOLFI, DANIELA MARÍA; SARRATEA, MARÍA BELÉN; IANNANTUONO LÓPEZ, LAURA VALERIA; TRINATARIO, SEBASTIÁN ; SACODOSSI, NATALIA ; CECILIA C. VILA; MARIELA BOLLINI; PAULA PÉREZ; JUAN M. LÁZARO MARTÍNEZ; MATÍAS OSTROWSKI; MALCHIODI, EMILIO LUIS; MARISA M. FERNANDEZ

Congreso; Reunión Conjunta de Sociedades de Biociencias; 2021

SAIC SAI AAFE NANOMED.AR

Coronavirus disease (COVID-19) caused by SARS-CoV-2 has emerged as a global pandemic. Theimmunological response has shown to be extremely complex and the severity of the casesrequires a quick diagnostic. Humoral parameters are especially important to analyze theharshness of the disease and to distinguish between infected and vaccinated patients.However, the human seroprevalence of antibodies against SARS-CoV-2 has shown a variableresponse among the population.Thus, this work aims to design surface plasmon resonance (SPR) assays to determine thepresence of antibodies anti-SARS-CoV-2 and their kinetic characteristics in patient sera. Inaddition, we evaluated the presence of pro-inflammatory cytokines in early infection.Sera were obtained from infected patients from Hospital Álvarez confirmed by specific PCRand evaluated by commercial tests. For the antibody analysis, assays using full-length r-Spikeprotein (20/20), r-RBD domain (19/20), and r-Nucleoprotein (15/20) immobilized into a CM5chip were performed. ELISAs and WBs were used to corroborate the results. SPR assays with r-RBD showed that 10% of the sera from infected patients display a distinct behavior, expressingkinetic association rates two times higher than control samples (10 4 vs 10 5 M -1 .s -1 , p